Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers

In patients with microsatellite instability-high (MSI-H) cancer, treatment with immune checkpoint inhibitors was associated with a pooled overall response rate of 41.5% (95% CI 34.9-48.4%), and pooled median progression-free survival of 4.3 months (3-6.8 months).

Source:

JAMA Oncology